Archimed sees 4.5x return with Vita Health Group exit

• Archimed acquired Vita in 2015
• Spire is an integrated hospital, medical and diagnostics services provider
• Archimed is an investment firm focused on healthcare sector

Archimed has exited its stake in Vita Health Group, a private UK healthcare provider, to Spire Healthcare Group for £74 million ($90 million; €85million).

Archimed acquired Vita (then known as RehabWorks) in 2015 by partnering with its founders, who retained a minority stake. The firm invested in Vita via its MED I fund.

Archimed has earned 4.5 times its total investment or a 25 percent annual return over eight years.

Vita reported average annual revenue growth of 33 percent and EBITDA growth of 49 percent (not including the impact of acquisitions), according to a release. Its projected revenues and EBITDA for the 2024 fiscal year are £100 million and £10 million, respectively.

“Working with management, we gave Vita a major technology edge, significantly boosting its profit margin in what was otherwise a low-margin, commoditised space,” said Robin Filmer-Wilson, Archimed partner.

Vita’s sale attracted a wide range of both financial and strategic buyers, the release said.

London-based Spire is an integrated hospital, medical and diagnostics services provider.

Archimed is an investment firm focused on healthcare sector. It has offices in New York, Singapore and France.

Deloitte acted as M&A advisor and Mills & Reeve as legal advisor to Archimed.